t(11;14)

MCL Literature Feed

888 papers on mantle cell lymphoma from PubMed. Updated daily.

ADCBCL2iBTKiCAR-TCDK4/6iCNSMRDPI3KiTP53-mutatedbiomarkersbispecificblastoidcase reportchemotherapyconsolidationelderlyepidemiologyfrontlinegenomicsguidelines
Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes.
Geoffrey Shouse·Human vaccines & immunotherapeutics·Dec 1, 2026
An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.
Toby A Eyre, Leyla Mohseninejad, Lianne Barnieh et al.·Journal of medical economics·Dec 1, 2026
Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe.

Quantifying the survival cost of delayed CAR T-cell reimbursement in Europe shows faster access for MCL patients would translate directly into more lives and life-years saved.

Yan Zhi Tan, Emily Breislin, Matthew Woods et al.·Journal of medical economics·Dec 1, 2026
CAR-Trelapsed/refractoryreal-worldhealth economicsepidemiology
Mechanisms of resistance to BTK inhibitors in B cell malignancies and emerging targeted strategies.
Qinyu Ni, Lixin Rui·Molecular therapy. Oncology·Sep 17, 2026
[Aggressive B-cell lymphomas with MYC gene cluster amplification: a clinicopathological analysis of eight cases].
Z H Wang, X D Teng, M C Zeng et al.·Zhonghua bing li xue za zhi = Chinese journal of pathology·Sep 8, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

High time for risk-adapted treatment in mantle cell lymphoma.
Ingrid Glimelius, Anna Nikkarinen, Leo Meriranta et al.·The Lancet. Haematology·Sep 2, 2026
Prostate lymphoma uncovered during urological encounters: Diagnostic challenges and clinical outcomes in a case series with systematic review of the literature.
Daniel Ajabshir, Gurpremjit Singh, Aravindh Rathinam et al.·Urologic oncology·Sep 2, 2026
Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis.
Fangfei Xu, Xiuping Zou, Yulin Yang et al.·Journal of cellular and molecular medicine·Sep 1, 2026
MAP3K14 (NIK) synonymous variants drive altered splicing to activate NF-κB in mature B-cell malignancies.
Eric Wenlong Li, Luuk Heitink, Esther Bandala-Sanchez et al.·Blood·Sep 1, 2026
FDA grants accelerated approval to BCL-2 inhibitor sonrotoclax for mantle cell lymphoma.
Leah Lawrence·Cancer·Sep 1, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.
Marie José Kersten, Maria T Kuipers, Pim G N J Mutsaers et al.·The Lancet. Haematology·Sep 1, 2026
Mantle cell lymphoma presenting as bullous pemphigoid: a rare paraneoplastic syndrome.
Avi Harisingani, Nishant Tiwari, Taylor Zak et al.·BMJ case reports·Aug 26, 2026
Covalent Bruton's tyrosine kinase inhibitor HZ-A-018 in patients with relapsed or refractory B cell malignancies: A multicenter phase I study.
Guolan Wu, JuYing Wei, Haiyan Yang et al.·iScience·Aug 21, 2026
BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives.
Tadeusz Robak, Anna Wolska-Washer, Paweł Robak·Cancers·Aug 20, 2026
B Cell Aplasia Following CAR T Cell Therapy: Incidence, Kinetics, Prognostic Implications, and Clinical Management.
Malak Khalifeh, Malini Surapaneni, Huda Salman·Cancers·Aug 19, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party.
Gloria Iacoboni, Pere Barba, Irma Khvedelidze et al.·Bone marrow transplantation·Aug 18, 2026
Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.
William Townsend, Nilanjan Ghosh, Martin Hutchings et al.·British journal of haematology·Aug 17, 2026
Clear cell sarcoma expressing CD79a and ALK: a haematolymphoid masquerade.
Zachary Yu, Han-Ho Chen, Jen-Chieh Lee et al.·Histopathology·Aug 14, 2026
Treatment Preferences for Relapsed/Refractory Mantle Cell Lymphoma Among Patients and Physicians in China: A Discrete Choice Experiment.
Jiachen Shao, Hui Peng, Li Zhou et al.·The patient·Aug 14, 2026
Preliminary study on efficacy and safety of pixantrone in relapsed/refractory aggressive B-cell lymphomas: multicenter, retrospective cohort study by Polish Lymphoma Research Group (PLRG).
Magdalena Witkowska, Senastin Szmit, Agnieszka Kołkowska-Leśniak et al.·Chinese clinical oncology·Aug 13, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance.
Marie-Kristin Tilch, Christian Schmidt, Marek Trneny et al.·BMC cancer·Aug 11, 2026
Moraxella nonliquefaciens Keratitis Due to Ocular Surface Disease in a Patient Treated with Zanubrutinib for Mantle Cell Lymphoma.
Ori Stern, Haggay Avizemer·Eye & contact lens·Aug 11, 2026
Bruton tyrosine kinase inhibitors plus chemoimmunotherapy in previously untreated younger mantle cell lymphoma patients: Single-centre clinical outcomes.
Kelly Chung, Amanda Chron, Anita Kumar et al.·British journal of haematology·Aug 7, 2026
How soon is now for new treatments for mantle cell lymphoma?
Peter Martin·Blood·Aug 6, 2026
Refining risk-stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches.
Alessia Moioli, Enrico Carazzai, Ilaria Mion et al.·Expert review of hematology·Aug 5, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

The BTK inhibitor acalabrutinib inhibits the expression of PD-L1 on myeloid cells during inflammation.
Sining Zhu, Judith Shakarchi Warman, Jaeyong Jung et al.·Molecular immunology·Aug 4, 2026
Treatment, Monitoring, and Management of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Evidence From a Multi-Country Needs Assessment.
Patrice Lazure, Toby A Eyre, Carsten Utoft Niemann et al.·Cancer reports (Hoboken, N.J.)·Aug 1, 2026
A 13-Year Review of Non-Diffuse Large B Cell Lymphomas of the Central Nervous System at a Tertiary Hospital: A Case Series Study.
Niloofar Sina, Chris Heyn, Zeina Ghorab et al.·Neuropathology : official journal of the Japanese Society of Neuropathology·Aug 1, 2026
Comparative Cardiovascular Safety and Exploratory Bleeding Outcomes of Ibrutinib, Acalabrutinib, and Zanubrutinib in Mantle Cell Lymphoma: A Propensity Score-Matched Real-World Analysis.
Anna Homeniuk, Amrit Sandhu, Leena Abdalla et al.·Cancer medicine·Aug 1, 2026
Bullous pemphigoid in patients who are frail: a case complicated by cerebral nocardiosis and Pneumocystis jirovecii pneumonia.
Simone Landini, Alessandro Magnatta, Alberto Corrà et al.·Skin health and disease·Aug 1, 2026
Page 1 of 30Next →